Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Net margin is calculated as Net Income divided by its Revenue. Zentiva's Net Income for the
three
months ended in Mar. 2025 was lei55 Mil. Zentiva's Revenue for the
three
months ended in Mar. 2025 was lei271 Mil. Therefore, Zentiva's net margin for the quarter that ended in Mar. 2025 was 20.35%.
The historical rank and industry rank for Zentiva's Net Margin % or its related term are showing as below:
BSE:SCD's Net Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 5.635 * Ranked among companies with meaningful Net Margin % only.
Zentiva (BSE:SCD) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Zentiva Net Margin % Related Terms
Zentiva Net Margin % Historical Data
* Premium members only.
The historical data trend for Zentiva's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSE:SCD vs ZTS, VTRS, NBIX: Net Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Zentiva's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zentiva Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zentiva's Net Margin % distribution charts can be found below:
* The bar in red indicates where Zentiva's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zentiva (BSE:SCD) has a Net Margin % of 20.35% as of Mar. 2025. Net margin is the ratio of total net income to net sales. View historical data on Zentiva and its competitors.
Is Zentiva's Net Margin % too high?
Zentiva's current Net Margin % is 20.35%. The Drug Manufacturers industry median Net Margin % is 5.64. Zentiva's value of 20.35% is 261.1% above this industry median. Overall, Zentiva has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Zentiva's Net Margin % compare to ZTS and VTRS?
Zentiva's Net Margin % of 20.35% can be compared against companies in the Drug Manufacturers industry. The industry median Net Margin % is 5.64. Zentiva's value of 20.35% is 261.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.64, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zentiva's current Net Margin % of 20.35% is 261.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Zentiva and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zentiva's current Net Margin % is 20.35%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zentiva stock overvalued right now?
Zentiva (BSE:SCD) has a current Net Margin % of 20.35%. The current Net Margin % is 20.35% and 261.1% above the Drug Manufacturers industry median of 5.64. Zentiva's overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Zentiva (BSE:SCD), the current Net Margin % is 20.35% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zentiva SA is a Romania-based producer of medicines on the local market. The product portfolio of Zentiva SA includes more than 126 products for human use, such as solids (tablets, capsules, and pellets), generic products, and injectable solutions. The company provides products for therapeutic areas such as Cardiovascular diseases, Anti-inflammatory and pain-relieving medications, urologists, Blood diseases, Gastrointestinal and metabolic disorders, Central nervous system, Medicines against infections, and Diseases of the respiratory system.
10GF Score
Get the complete analysis for BSE:SCD
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSE:SCD has been successfully added to your 
